Each tablet contains Olmesartan 20 mg + Metoprolol 25 mg or 50 mg.

Olmat MT Tablets combine Olmesartan, a selective angiotensin II receptor blocker (ARB), with Metoprolol, a cardioselective beta₁-adrenergic receptor blocker, to provide effective once-daily management of essential hypertension. Olmesartan reduces blood pressure by blocking the vasoconstrictor effects of angiotensin II, while Metoprolol lowers heart rate, cardiac output, and myocardial oxygen demand. This complementary combination provides sustained blood pressure control while reducing cardiovascular workload.

Olmat MT Tablets are indicated for the treatment of essential hypertension.

Olmesartan is a selective angiotensin II type 1 (AT1) receptor antagonist that blocks the vasoconstrictor effects of angiotensin II by selectively preventing its binding to AT1 receptors in vascular smooth muscle, thereby reducing peripheral vascular resistance and lowering blood pressure. Metoprolol is a beta₁-selective (cardioselective) adrenergic receptor blocker that exerts its antihypertensive effects by reducing heart rate and cardiac output at rest and during exercise, inhibiting isoproterenol-induced tachycardia, reducing systolic blood pressure during exercise, and suppressing reflex orthostatic tachycardia. The combined actions of these agents provide effective and sustained blood pressure reduction.

The recommended dosage is one tablet once daily, preferably taken with food, or as directed by the treating physician.

Olmat MT Tablets are contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), or known hypersensitivity to Olmesartan, Metoprolol, or any component of the formulation.